肿瘤组织中Nectin-4的表达模式及治疗方法

IF 9.1 1区医学 Q1 ONCOLOGY

Cancer letters Pub Date : 2025-04-08 DOI:10.1016/j.canlet.2025.217681

Mina Nikanjam , Judith Pérez-Granado , Mark Gramling , Bruno Larvol , Razelle Kurzrock

{"title":"肿瘤组织中Nectin-4的表达模式及治疗方法","authors":"Mina Nikanjam , Judith Pérez-Granado , Mark Gramling , Bruno Larvol , Razelle Kurzrock","doi":"10.1016/j.canlet.2025.217681","DOIUrl":null,"url":null,"abstract":"<div><div>Nectin-4 is a transmembrane receptor that is implicated in migration, adhesion, and proliferation of tumor cells. It has minimal expression in healthy adult tissue but is overexpressed in a number of cancers, with higher expression levels seen in breast, bladder, colorectal, gallbladder, gastric, and non-small cell lung cancers. Enfortumab vedotin is an antibody-drug conjugate against nectin-4 that has been studied in a number of solid tumors and is FDA-approved for advanced urothelial cancers (including in combination with pembrolizumab). There are a number of other nectin-4-targeting agents under investigation. This review summarizes nectin-4 expression (membranous and cytoplasmic)/amplification in cancer and its potential as a response biomarker, as well as clinical trials of enfortumab vedotin and novel nectin-4 targeting agents. Biomarker-driven approaches merit investigation for nectin-4 directed across tumor types.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"622 ","pages":"Article 217681"},"PeriodicalIF":9.1000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nectin-4 expression patterns and therapeutics in oncology\",\"authors\":\"Mina Nikanjam , Judith Pérez-Granado , Mark Gramling , Bruno Larvol , Razelle Kurzrock\",\"doi\":\"10.1016/j.canlet.2025.217681\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Nectin-4 is a transmembrane receptor that is implicated in migration, adhesion, and proliferation of tumor cells. It has minimal expression in healthy adult tissue but is overexpressed in a number of cancers, with higher expression levels seen in breast, bladder, colorectal, gallbladder, gastric, and non-small cell lung cancers. Enfortumab vedotin is an antibody-drug conjugate against nectin-4 that has been studied in a number of solid tumors and is FDA-approved for advanced urothelial cancers (including in combination with pembrolizumab). There are a number of other nectin-4-targeting agents under investigation. This review summarizes nectin-4 expression (membranous and cytoplasmic)/amplification in cancer and its potential as a response biomarker, as well as clinical trials of enfortumab vedotin and novel nectin-4 targeting agents. Biomarker-driven approaches merit investigation for nectin-4 directed across tumor types.</div></div>\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"622 \",\"pages\":\"Article 217681\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2025-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304383525002472\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383525002472","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Nectin-4是一种跨膜受体，参与肿瘤细胞的迁移、粘附和增殖。它在健康成人组织中表达极低，但在许多癌症中过表达，在乳腺癌、膀胱癌、结肠直肠癌、胆囊癌、胃癌和非小细胞肺癌中表达水平较高。Enfortumab vedotin是一种针对nectin-4的抗体-药物偶联物，已在许多实体瘤中进行了研究，并且已被fda批准用于晚期尿路上皮癌（包括与pembrolizumab联合使用）。还有许多其他的连接素-4靶向制剂正在研究中。本文综述了nectin-4在癌症中的表达（膜和细胞质）/扩增及其作为反应生物标志物的潜力，以及enfortumab vedotin和新型nectin-4靶向药物的临床试验。生物标志物驱动的方法值得研究针对肿瘤类型的nectin-4。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Nectin-4 expression patterns and therapeutics in oncology

Nectin-4 is a transmembrane receptor that is implicated in migration, adhesion, and proliferation of tumor cells. It has minimal expression in healthy adult tissue but is overexpressed in a number of cancers, with higher expression levels seen in breast, bladder, colorectal, gallbladder, gastric, and non-small cell lung cancers. Enfortumab vedotin is an antibody-drug conjugate against nectin-4 that has been studied in a number of solid tumors and is FDA-approved for advanced urothelial cancers (including in combination with pembrolizumab). There are a number of other nectin-4-targeting agents under investigation. This review summarizes nectin-4 expression (membranous and cytoplasmic)/amplification in cancer and its potential as a response biomarker, as well as clinical trials of enfortumab vedotin and novel nectin-4 targeting agents. Biomarker-driven approaches merit investigation for nectin-4 directed across tumor types.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer letters 医学-肿瘤学

CiteScore

17.70

自引率

2.10%

发文量

427

审稿时长

15 days

期刊介绍： Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research. Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy. By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.